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Abstract: The COVID-19 pandemic may be of particular concern for pregnant and breastfeeding
women. We aimed to explore their beliefs about the coronavirus and COVID-19 vaccine willingness
and to assess the impact of the pandemic on perinatal experiences and practices. A multinational,
cross-sectional, web-based study was performed in six European countries between April and July
2020. The anonymous survey was promoted via social media. In total, 16,063 women participated
(including 6661 pregnant and 9402 breastfeeding women). Most responses were collected from
Belgium (44%), Norway (18%) and the Netherlands (16%), followed by Switzerland (11%), Ireland
(10%) and the UK (3%). Despite differences between countries, COVID-19 vaccine hesitancy was
identified among 40–50% of the respondents at the end of the first wave of the pandemic and was
higher among pregnant women. Education level and employment status were associated with vaccine
hesitancy. The first wave had an adverse impact on pregnancy experiences and disrupted access to
health services and breastfeeding support for many women. In the future, access to health care and
support should be maintained at all times. Evidence-based and tailored information on COVID-19
vaccines should also be provided to pregnant and breastfeeding women to avoid unfounded concerns
about the vaccines and to support shared decision making in this population.
Keywords: COVID-19; SARS-CoV-2; pregnancy; breastfeeding; counseling; maternity care; commu-
nity health services; public health; primary health care; vaccine hesitancy
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1. Introduction
Millions of women have become pregnant, given birth and initiated breastfeeding
since the start of the COVID-19 pandemic at the end of 2019 [1]. Nonetheless, the current
evidence delineating the potential risks following SARS-CoV-2 infection in pregnancy still
remains conflicting. While some studies concluded that pregnant women are at increased
risk of severe COVID-19 including ICU admission and mechanical ventilation [2,3], other
studies did not find such an association [4]. SARS-CoV-2 infection in pregnancy might also
be associated with an increased risk of pregnancy complications such as preterm birth and
caesarian section or could lead to vertical transmission in rare cases [5–7], underlining that
any fetal–maternal risks of COVID-19 in pregnancy cannot be excluded. With regard to
breastfeeding, there is no evidence of vertical transmission of replication-competent virus
through breastmilk or that breast milk would be a source of infection for the infant [8].
In fact, SARS-CoV-2 neutralizing antibodies have been found in breastmilk of COVID-19
mothers [9]. Even in the early stages of the pandemic, mothers were advised to initiate or
continue to breastfeed, even in case of suspected or confirmed COVID-19 where hygiene
measures are key [10].
Over the last year, the pandemic has forced policy makers to impose containment
measures to curb the transmission of the virus. Some of the measures included the obliga-
tion to work from home, the closure of schools and the abrupt discontinuation of people’s
recreational and social life [11]. Although the “lockdown” had positive effects on reducing
virus transmission [11,12], it may have increased mental health distress among pregnant
and breastfeeding women [13–16]. In addition to the potential adverse impact on emotional
wellbeing, the restrictions may also have affected women’s perinatal experiences and/or
breastfeeding practices or may have been disruptive to women’s access to health services
and the extent of support received [17,18]. However, pregnant and breastfeeding women
do have a continuous need for medical follow-up, even in times of limited resources.
Hence, insight into the impact of the pandemic on perinatal experiences and practices is
vital for healthcare professionals (HCPs) and policy makers to identify consequences and
challenges for perinatal care.
Since the outbreak of SARS-CoV-2, people have been eagerly anticipating the re-
lease of COVID-19 vaccine candidates to bring the pandemic to an end. Meanwhile, four
vaccines have obtained market authorization in Europe (i.e., Pfizer/BioNTech, Moderna,
Oxford/AstraZeneca and Johnson & Johnson vaccines) [19–21]. To end the pandemic, it
is paramount that vaccine uptake is high enough to achieve herd immunity [22]. Vaccine
coverage required for herd immunity depends on vaccine efficacy, duration of vaccine
protection and the reproduction number of the virus and current estimates for SARS-CoV-2
range between 60% and 90% of the population [23]. Meanwhile, various international
guidelines have been published proposing priority groups for vaccination, such as front-
line HCPs, persons living in retirement facilities and patients suffering from conditions
predisposing to severe disease. While the available guidelines do not recommend routine
vaccination of all pregnant and breastfeeding women due to the lack of safety data, vacci-
nating women with a high risk of occupational exposure to the virus (e.g., health and social
care personnel) or with a high risk of severe illness due to underlying conditions could be
considered on an individualized basis [24–27]. However, it is still unclear whether women
themselves are willing to get the vaccine during pregnancy or breastfeeding. Despite
several studies on vaccine willingness in the general population [28,29], pregnant and
breastfeeding women’s perceptions remain unknown.
A multinational study was conducted to explore pregnant and breastfeeding women’s
beliefs about the coronavirus and COVID-19 vaccine willingness and to assess the impact
of the pandemic on self-reported pregnancy and breastfeeding experiences, breastfeeding
practices, access to health services and support during the breastfeeding period. Addi-
tionally, factors related to COVID-19 vaccine willingness in this perinatal cohort were
explored.
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2. Methods
2.1. Study Design and Sample
A multinational, cross-sectional, web-based study was performed in Ireland (IE), Nor-
way (NO), Switzerland (CH), the Netherlands (NL) and the United Kingdom (UK) between
16 June and 14 July 2020, and in Belgium (BE) between 10 April and 31 May 2020. Pregnant
and breastfeeding women up to three months postpartum (or up to 4 weeks after delivery
in Belgium) and who were older than 18 years were eligible to participate. Data collection
occurred through a uniform, anonymous web survey. The survey was promoted via social
media and websites commonly visited by pregnant women and mothers; more information
on the survey dissemination has been described elsewhere [16,17]. All participants pro-
vided an online informed consent prior to survey initiation. Ethical approval was waived
in most countries as the survey was anonymous, except for Belgium (EC Research UZ/KU
Leuven; S63966; 10 April 2020) and Ireland (Rotunda Hospital Research Ethics Committee;
REC-2020–017; 23 June 2020). Study reporting is performed according to the STROBE
guidelines (Strengthening the Reporting of Observational Studies in Epidemiology) [30].
2.2. Survey
The survey was part of a multinational COVID-19 research project aimed at providing
insight into (1) pregnant and breastfeeding women’s mental health status during the
pandemic; (2) women’s beliefs about the coronavirus and COVID-19 vaccine willingness;
(3) the self-reported impact of the pandemic on the following four thematic areas of
maternity care: “pregnancy and breastfeeding experiences”, “breastfeeding practices”,
“access to health services” and “the extent of support during the breastfeeding period”. The
findings on mental health status and the impact on the four thematic areas, as reported by
the Belgian participants, have already been published [13,16,17]. The current manuscript
focuses on pregnant and breastfeeding women’s beliefs about the coronavirus and COVID-
19 vaccine willingness in pregnancy and breastfeeding (for all countries) and on the self-
reported impact of the pandemic on the four thematic areas of maternity care (for all
countries except Belgium). The procedures related to pilot testing and survey translation
have been described elsewhere [16,17]. The survey was available in the official languages
of the participating countries, i.e., English, German, French, Italian, Norwegian and Dutch.
The pregnancy and breastfeeding survey is included in Figure S1 (Supplementary Material).
2.3. Measures
The surveys for pregnant and breastfeeding women were similar and were both
exploratory. Information on sociodemographic characteristics was collected, including
country, maternal age, relationship status, professional status, education level, smoking in
pregnancy or breastfeeding. Information on the health and reproductive characteristics
was also collected, including being tested for SARS-CoV-2 and the corresponding result,
chronic illness, gravidity, planned pregnancy, gestational trimester, current breastfeeding
duration and previous breastfeeding experience. Highest level of education attainment
was categorized into low, medium or high according to national definitions. A chronic
illness was considered a health condition that already existed before pregnancy.
Women’s perceptions about the coronavirus and COVID-19 vaccine willingness were
assessed by seven statements (five in the pregnancy and two in the breastfeeding survey),
rated on a 4-point Likert scale ranging from “strongly agree” to “strongly disagree”.
Women with a previous pregnancy or breastfeeding experience were asked to what
extent the coronavirus affected their current pregnancy or breastfeeding experience, rated
on a 4-point Likert scale ranging from “no influence at all” to “large influence”. With regard
to breastfeeding practices, women were asked whether the pandemic had an impact on
(breast)feeding patterns, along with listing reasons explaining any changes. Women who
were still breastfeeding were also questioned regarding to what extent they had considered
stopping breastfeeding or breastfeeding for a longer period of time due to SARS-CoV-2.
These questions were rated on a 4-point Likert scale ranging from “not considered at all”
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to “strongly considered”. Women who indicated that the pandemic affected their access to
health services or support during breastfeeding were asked how their medical follow-up
(more or less follow-up or no influence) and/or support during breastfeeding (more or
less support or no influence) was affected. The remaining questions examined whether
women still experienced restrictions of their normal activities, as well as whether and to
what extent the pandemic affected their income (negatively or positively, limited or large
influence).
All participants who completed the breastfeeding survey, including those who recently
stopped breastfeeding, were grouped into the category “breastfeeding women”. The
breastfeeding duration was categorized into “≤6 weeks”, “between 6 weeks and 6 months”
and “>6 months”.
2.4. Data Analysis
Descriptive statistics were used to analyze women’s sociodemographic, health and
reproductive characteristics. The results of the statements on women’s beliefs about the
coronavirus and COVID-19 vaccine willingness were dichotomized and tabulated, and per-
centages were calculated for each statement and country. Percentages were also calculated
per country for the results on the four thematic areas of maternity care, including for each
type of HCP (see “access to health services”) and type of support (see “support during
the breastfeeding period”). Univariable and multivariable logistic regression was per-
formed to identify factors related to COVID-19 vaccine willingness with regard to pregnant
and breastfeeding women’s sociodemographic, health and reproductive characteristics.
Results were shown as crude (OR) and adjusted odds ratios (aOR) and 95% confidence
intervals (CI). All sociodemographic, health and reproductive characteristics were used
in the univariable analyses. Only significant variables (p ≤ 0.05) were included in the
adjusted models, such as country, maternal age, professional status, highest education
level, gravidity, current breastfeeding duration and previous breastfeeding experience.
Multicollinearity of the variables was checked using chi-square tests. The variable “chronic
illness” was not addressed in the Belgian survey and was therefore not included in the
calculation of the adjusted models. All survey responses, including those with incomplete
results, were included in the analysis. Data analysis was performed using SPSS Statistics
version 26 (IBM Corp, Armonk, NY, USA).
3. Results
3.1. Characteristics of the Participants
In total, 16 063 women participated in the study (i.e., 6661 pregnant and 9402 breast-
feeding women) (see Table 1). Most responses were collected from Belgium (44%), Norway
(18%) and the Netherlands (16%), followed by Switzerland (11%), Ireland (10%) and the
UK (3%). More than half of the pregnant women were in their third trimester (51%),
while 91% of the mothers were still breastfeeding at the time of survey completion. Most
breastfed infants were between 6 weeks and 6 months old (44%). A chronic illness was
reported by 19% and 16% of the pregnant and breastfeeding women, respectively. With
regard to COVID-19, less than 1% had tested positive for SARS-CoV-2. One-third of the
professionally active respondents were employed in healthcare (35%). A comparison of
the sociodemographic characteristics of the participants with country-specific birthing
population data is shown in Table S1 (Supplementary Material). Differences related to
relationship status, professional status, education attainment and smoking in pregnancy.
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Table 1. Overview of the characteristics of the participants (n = 16 063).
Pregnant Women (n = 6 661) Breastfeeding Women (n = 9 402)
% (n) % (n)
Sociodemographic characteristics
Country
Belgium 41.3 (2754) 45.4 (4268)
Ireland 10.4 (692) 9.7 (912)
Norway 20.2 (1344) 15.8 (1485)
Switzerland 8.5 (563) 12.7 (1193)
The Netherlands 17.6 (1173) 15.4 (1447)
United Kingdom 2.0 (135) 1.0 (97)
Maternal age (years)
18–25 6.2 (373) 3.2 (266)
26–30 36.7 (2191) 29.1 (2436)
31–35 42.1 (2515) 46.7 (3907)
36–40 13.5 (806) 18.0 (1504)
>40 0.1 (88) 3.0 (254)
Relationship status
Partner 97.8 (5868) 97.7 (8213)
No partner 2.2 (132) 2.3 (191)
Professional status
Professionally active, not in
healthcare 59.3 (3499) 58.4 (4837)
Professionally active, in
healthcare 33.0 (1950) 31.6 (2618)
Not professionally active 7.7 (454) 10.0 (826)
Education level
Low 3.2 (190) 3.9 (319)
Medium 20.6 (1217) 21.0 (1734)
High 76.2 (4494) 75.1 (6194)
Smoking in
pregnancy/breastfeeding
Yes 2.5 (151) 3.5 (296)




Tested 6.5 (421) 8.9 (803)
Tested positive 0.6 (38) 0.6 (52)
Chronic illnessa
Yes 19.2 (623) 16.1 (665)
No 80.8 (2623) 83.9 (3473)
Gravidity
Primigravida 47.8 (3183) N/A
Multigravida 52.2 (3478) N/A
Planned pregnancy
Yes 85.4 (5690) N/A
No 14.6 (971) N/A
Gestational trimester
First trimester (0–12 weeks) 9.9 (653) N/A
Second trimester (13–27 weeks) 38.9 (2558) N/A
Third trimester (28–40 weeks) 51.1 (3357) N/A
Current breastfeeding duration
≤6 weeks N/A 17.5 (1512)
Between 6 weeks–6 months N/A 43.6 (3758)
>6 months N/A 38.9 (3357)
Previous breastfeeding
experience
Yes N/A 55.1 (5113)
No N/A 44.9 (4173)
Numbers may not add up due to missing values. a information about the variable “chronic illness” was not
available for Belgian participants. N/A: not applicable.
3.2. Beliefs about the Coronavirus and COVID-19 Vaccine Willingness
While 54% of the pregnant women agreed that a coronavirus infection during preg-
nancy could affect the development of the unborn child, 86% believed that this could be
possible in cases of severe COVID-19 in pregnancy. Nonetheless, 96% of the pregnant
women would not consider a termination of pregnancy in case of a SARS-CoV-2 infection
in the first trimester.
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At the time of survey completion, 61% of the pregnant respondents answered that
they would be willing to get vaccinated against SARS-CoV-2 in pregnancy if a vaccine was
available (see Table 2). If Belgium was excluded from the sample (i.e., because the data
were collected at a different time), the proportion of women likely to be administered a
COVID-19 vaccine in pregnancy dropped to 49%. With regard to breastfeeding women,
69% was willing to get vaccinated against SARS-CoV-2 while breastfeeding if a vaccine
was available (see Table 2). If Belgium was again excluded from the sample, the percentage
dropped to 59%. Although French-speaking participants were only a small part of the
Belgian sample (11–13%), they were less likely to get a vaccine during pregnancy (49%)
or breastfeeding (55%) compared to their Dutch-speaking counterparts (83% and 82%,
respectively). Finally, 86% and 81% of all pregnant and breastfeeding women were not
willing to participate in a scientific study testing medicines against COVID-19. A detailed
overview of the country-specific results is included in Table S2 (Supplementary Material).
Table 2. COVID-19 vaccine willingness among pregnant and breastfeeding women.
Statement (Strongly) Agree
Total BE NO UK IE NL CH
“If a coronavirus vaccine was available, I would
get the vaccine during pregnancy.” (n = 6420)
61.4% 78.1% 55.1% 53.9% 51.1% 48.6% 29.7%
−3943 −2150 −741 −62 −316 −521 −153
“If a coronavirus vaccine was available, I would
get the vaccine during breastfeeding.” (n = 8980)
68.8% 79.2% 67.6% 79.7% 67.1% 60.4% 38.6%
−6174 −3379 −1004 −63 −536 −793 −399
Results are expressed as % (absolute numbers). The statements were rated on a 4-point Likert scale ranging from (strongly) agree to
(strongly) disagree. Only the percentages of women (strongly) agreeing are shown in the table. BE = Belgium; NO = Norway; UK = United
Kingdom; IE = Ireland; NL = the Netherlands; CH = Switzerland.
With regard to factors related to vaccine willingness (see Table 3), a higher likelihood
of getting a COVID-19 vaccine during pregnancy or breastfeeding was observed among
women living in Belgium (measured in April–May). Primigravida pregnant women and
breastfeeding women who delivered in the last 6 months were also more likely to be willing
to get a vaccine. In contrast, pregnant and breastfeeding women with low and medium
levels of education and without employment were less in favor of COVID-19 vaccination.
Finally, pregnant women working in healthcare were also less likely to be willing to get
a vaccine compared to women employed outside healthcare, although the difference in
absolute numbers was very limited (62% vs. 65%, see Supplementary Material Table S3).
In the univariable analyses, pregnant women who had a positive test result for SARS-
CoV-2 were more in favor of getting a COVID-19 vaccine in pregnancy compared to
women without a positive test result, but the finding was not significant (OR 1.65; 95% CI:
0.80–3.43). A similar observation was noted among breastfeeding women (OR 1.23; 95%
CI: 0.67–2.28).
Table 3. Factors related to COVID-19 vaccine willingness among pregnant and breastfeeding women.
Characteristic
Pregnant Women Breastfeeding Women
OR * (95% CI) aOR ** (95% CI) OR * (95% CI) aOR *** (95% CI)
Country
Belgium Ref Ref Ref Ref
Ireland 0.29 (0.24–0.35) 0.33 (0.27–0.40) 0.54 (0.46–0.63) 0.60 (0.49–0.74)
Norway 0.35 (0.30–0.40) 0.35 (0.30–0.41) 0.55 (0.48–0.63) 0.54 (0.47–0.63)
Switzerland 0.12 (0.10–0.15) 0.15 (0.11–0.19) 0.17 (0.14–0.19) 0.20 (0.17–0.25)
The Netherlands 0.27 (0.23–0.31) 0.29 (0.25–0.34) 0.40 (0.35–0.46) 0.42 (0.36–0.49)
United Kingdom 0.33 (0.23–0.48) 0.32 (0.21–0.49) 1.04 (0.60–1.80) 1.16 (0.60–2.26)
Maternal age (years)
18–25 Ref Ref Ref Ref
26–30 1.41 (1.13–1.76) 0.94 (0.73–1.20) 1.51 (1.17–1.96) 1.15 (0.84–1.57)
31–35 1.47 (1.18–1.83) 1.05 (0.81–1.35) 1.60 (1.24–2.06) 1.27 (0.93–1.73)
36–40 1.21 (0.95–1.55) 1.05 (0.79–1.40) 1.60 (1.22–2.10) 1.44 (1.04–2.01)
>40 0.89 (0.56–1.41) 0.76 (0.45–1.28) 1.27 (0.89–1.82) 1.23 (0.79–1.89)
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Table 3. Cont.
Characteristic
Pregnant Women Breastfeeding Women
OR * (95% CI) aOR ** (95% CI) OR * (95% CI) aOR *** (95% CI)
Professional status
Active, but not in healthcare Ref Ref Ref Ref
Active in healthcare 0.90 (0.80–1.01) 0.84 (0.74–0.95) 0.95 (0.85–1.05) 0.91 (0.81–1.03)
Not professionally active 0.55 (0.45–0.67) 0.71 (0.57–0.89) 0.51 (0.44–0.60) 0.69 (0.57–0.82)
Highest education level
Low 0.26 (0.19–0.35) 0.58 (0.41–0.81) 0.23 (0.18–0.28) 0.54 (0.41–0.73)
Medium 0.57 (0.50–0.64) 0.71 (0.62–0.83) 0.60 (0.54–0.68) 0.68 (0.59–0.78)
High Ref Ref Ref Ref
Chronic illness
Yes 0.99 (0.83–1.18) N/A 1.25 (1.05–1.49) N/A
Gravidity
Primigravida 1.15 (1.04–1.27) 1.16 (1.03–1.31) N/A N/A
Current breastfeeding duration
≤6 weeks N/A N/A 1.84 (1.58–2.13) 1.73 (1.46–2.05)
Between 6 weeks–6 months N/A N/A 1.29 (1.16–1.44) 1.40 (1.24–1.58)
>6 months N/A N/A Ref Ref
Previous breastfeeding
experience
Yes N/A N/A 0.90 (0.82–0.98) 0.92 (0.82–1.04)
N/A = not available; * OR = crude odds ratio; ** aOR = adjusted odds ratio, adjusted for country, maternal age, professional status, highest
education level and gravidity. *** aOR adjusted for country, maternal age, professional status, highest education level, current breastfeeding
duration and previous breastfeeding experience. The bold numbers indicate aORs not including 1. Only significant variables were included
in the adjusted models and are shown in the table. Information on “chronic illness” was not available for Belgian respondents and was
therefore not included in the adjusted models. Reference groups for the variables “chronic illness”, “gravidity” and “previous breastfeeding
experience” were no chronic illness, multigravida and no previous breastfeeding experience, respectively.
3.3. Impact on Pregnancy and Breastfeeding Experiences
In total, 52% of those who had already been pregnant (n = 2044) reported that the
pandemic had a (rather) large impact on their current pregnancy experience compared
to previous pregnancies (UK: 75%; IE: 71%; NO: 64%; CH: 37%; NL: 34%). Main reasons
negatively affecting the current pregnancy experience were the absence of the partner
during antenatal check-ups and ultrasounds, less medical follow-up, increased anxiety
or stress due to the current situation, social isolation, less support, as well as being more
cautious when interacting with other people (see Table S4 in the Supplementary Material
for a list of representative statements). In contrast, only 17% of the women with a previous
breastfeeding experience (n = 2786) indicated that the pandemic had a (rather) large impact
on how they dealt with breastfeeding (IE: 32%; UK: 28%; NO: 17%; NL: 9%; CH: 9%).
3.4. Impact on Breastfeeding Practices
Overall, 96% of the women (n = 4623) indicated that the infant’s diet had not changed
due to the pandemic (CH: 98%; NO: 98%; NL: 96%; IE: 93%; UK: 92%). However, in
cases where the mother indicated the diet had changed due to the pandemic (n = 164),
infants more often received mother’s milk in 73% of the cases as compared to before
the coronavirus outbreak. Moreover, 90% of the mothers who quit breastfeeding in the
preceding three months (n = 446) reported that breastfeeding cessation was not the result
of the pandemic (NO: 95%; CH: 95%; NL: 92%; UK: 92%; IE: 81%). Main reasons for
breastfeeding cessation or decline were insufficient support from an HCP with regard to
breastfeeding and/or related issues, and other childcare responsibilities or circumstances
at home. Main reasons for an increase in giving breastmilk were that being or working
from home during the pandemic facilitated breastfeeding, and women’s beliefs to protect
the infant against the coronavirus through mother’s milk (see Supplementary Material
Table S4). Finally, 96% of the women (n = 4576) had not yet considered (at all) stopping
giving breastmilk because of the coronavirus (NL: 98%; NO: 98%; CH: 98%; UK: 89%; IE:
89%). In fact, 49% had already (strongly) considered giving breastmilk for a longer period
of time because of the coronavirus (IE: 60%; NO: 49%; UK: 48%; CH: 47%; NL: 44%).
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3.5. Impact on Access to Health Services
Overall, 59% of the pregnant women (n = 3844) cited that the pandemic affected their
access to health services to some extent (UK: 93%; IE: 79%; NL: 59%; NO: 51%; CH: 48%).
Women mainly reported less medical follow-up by midwives (67%), general practitioners
(GPs) (51%) and obstetricians (44%) (see Table 4). In each country, less than 10% reported
having received more medical follow-up from any type of HCP.
Table 4. Impact of the pandemic on access to health services during pregnancy and lactation (n = 8709).
Healthcare Professional
More Follow-Up Less Follow-Up No Influence
Pregnancy Lactation Pregnancy Lactation Pregnancy Lactation
Midwife 4.9% (93) 5.2% (95) 67.3% (1290) 65.9% (1206) 27.8% (533) 28.9% (530)
General practitioner 6.5% (98) 3.4% (71) 50.6% (764) 66.5% (1381) 42.9% (648) 30.1% (624)
Obstetrician 6.1% (72) 2.9% (40) 43.5% (515) 43.3% (588) 50.4% (597) 53.7% (729)
Medical specialist 7.7% (66) 3.0% (30) 36.5% (313) 47.5% (482) 55.8% (479) 49.5% (502)
Perinatal organization* N/A 3.3% (37) N/A 72.0% (811) N/A 24.8% (279)
Lactation consultant N/A 3.1% (55) N/A 69.0% (1230) N/A 27.9% (497)
Pediatrician N/A 3.5% (57) N/A 38.1% (612) N/A 58.3% (937)
N/A = not applicable. Results are expressed as % (absolute numbers). Percentages were calculated using as denominator the total number
of women who reported that their access to health services was affected by the pandemic and who indicated being counseled by this type
of professional. * The variable “perinatal organization” was not included in the Norwegian survey.
Of all breastfeeding women (n = 4865), 54% felt that their access to health services
during the breastfeeding period was affected by the pandemic (UK: 86%; IE: 86%; NO:
70%; CH: 31%; NL: 30%). Women mainly reported less medical follow-up by perinatal
organizations (72%), lactation consultants (69%), GPs (67%) and midwives (66%) (see
Table 4). In each country, less than 10% reported having received more medical follow-up
from any type of HCP. An overview of the routine antenatal care in the countries along with
the COVID-19 regulations in maternity care during the pandemic is provided in Figure S2
(Supplementary Material). The country-specific results of the self-reported impact of the
pandemic on access to health services are included in Table S5 and Table S6 (Supplementary
Material).
3.6. Impact on Support during the Breastfeeding Period
Overall, 42% of the breastfeeding women (n = 4817) indicated that the pandemic
affected the support they received during the breastfeeding period to some extent (IE:
74%; UK: 74%; NO: 42%; CH: 36%; NL: 24%). Women mainly reported less support from
friends (81%), perinatal organizations (81%) and maternity care services at home (76%)
(see Table 5). In each country, a maximum of 15% reported receiving more of any type of
support compared to before the pandemic. An overview of the country-specific results of
the self-reported impact of the pandemic on support during breastfeeding is included in
Table S7 (Supplementary Material).
Table 5. Impact of the pandemic on the extent of support during breastfeeding (n = 2008).
Support Provided by More Support Less Support No Influence
Friends 5.4% (101) 81.3% (1535) 13.3% (251)
Perinatal organization 3.1% (45) 80.5% (1165) 16.4% (237)
Maternity care services at home 3.4% (57) 75.8% (1273) 20.8% (350)
Family 11.6% (224) 73.5% (1415) 14.9% (286)
Results are expressed as % (absolute numbers). Percentages were calculated using as denominator the total
number of women who reported that the support they received during the breastfeeding period was affected by
the pandemic and who indicated that this type of support was applicable to them during breastfeeding.
3.7. Impact on Women’s Personal Life and Financial Situation
At the time of survey completion, 81% of the pregnant women (n = 3626) indicated
that their normal activities were (still) restricted as compared to before the pandemic (UK:
95%; IE: 94%; NO: 87%; CH: 69%; NL: 68%); this was the case for 82% of the breastfeeding
women (n = 4644) (UK: 97%; IE: 95%; NO: 92%; NL: 73%; CH: 69%). In general, 70% of
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the pregnant women indicated having personally restricted themselves to only essential
journeys during the pandemic on top of the measures imposed by the government (IE: 86%;
UK: 83%; CH: 69%; NO: 69%; NL: 60%). The corresponding percentage for breastfeeding
women was 57% (IE: 66%; NL: 59%; NO: 58%; UK: 52%; CH: 45%).
With regard to women’s financial situation, 22% of the pregnant women (n = 3129)
cited that the pandemic affected their professional income to some extent (UK: 40%; IE:
32%; NO: 23%; CH: 21%; NL: 14%), with a predominantly negative (90%) but limited (58%)
impact noted across countries. Likewise, 18% of the breastfeeding women (n = 3842) felt
that the pandemic affected their professional income (UK: 25%; IE: 24%; NO: 20%; CH:
16%; NL: 12%). In this group, a negative (89%) but limited (58%) effect was also reported.
4. Discussion
4.1. Main Findings
This multinational study aimed to explore pregnant and breastfeeding women’s beliefs
about the coronavirus and COVID-19 vaccine willingness and to assess the impact of the
pandemic on self-reported perinatal experiences and practices. A uniform, cross-sectional
web survey was distributed across six European countries during the first wave of the
pandemic (April–July 2020) [31], capturing in total more than 16,000 unique responses in-
cluding statements reflecting women’s experiences and practices throughout the pandemic.
To the best of our knowledge, this is the largest study reported so far exploring COVID-19
vaccine willingness in a perinatal population.
Overall, about 60–70% of the women indicated that they were willing to get a COVID-
19 vaccine during pregnancy or breastfeeding; all countries had a larger proportion of
breastfeeding women in favor of the vaccine. However, and as previously shown [32,33],
substantial differences were observed across countries (range: 30–80%), and even between
communities within the same country (Belgium, range: 49–82%). Differences between
countries may be, at least partially, explained by the different timing of study execution
and consequently by the different stage of the pandemic with different incidence rates
of COVID-19 cases and containment measures in place at the time of survey completion
(Belgium = April–May 2020, i.e., at the peak of the first wave of the pandemic when a strict
lockdown was still in effect; other countries = June–July 2020, i.e., at the end of the first wave
of the pandemic in most countries, except the UK, when restrictions were mostly lifted)
(see Supplementary Material Table S8 and Figure S3) [31]. This hypothesis is supported by
two recent longitudinal studies on the public’s likelihood of getting a COVID-19 vaccine,
showing a decline of 17% in vaccine willingness between April and September 2020 [29,32].
A recent large-scale modeling study also acknowledged that vaccine confidence can vary
over time and across countries [34]. In our sample, the percentages observed during the
first wave of the pandemic (i.e., in Belgium, 79%) are in line with estimates calculated at
that time in other samples within the general public in Europe and America (74%) [29,35].
When assessing our data collected at the end of the first wave (i.e., in all countries except
Belgium), vaccine willingness dropped to 50–60% of pregnant and breastfeeding women.
For breastfeeding women, the observed likelihood of getting a vaccine whilst breastfeeding
(59%) is quite similar to estimates measured within the general public in European (68%)
and American samples (62%) at that time [29,32]. However, COVID-19 vaccine willingness
during pregnancy, as measured in our sample (49% if excluding Belgian data), is lower
than observed in the other samples at that time (62–68%) [29,32], but in line with estimates
calculated among an international cohort of pregnant women in October–November 2020
(52%) [33]. Thus, our findings do not only demonstrate that COVID-19 “vaccine hesitancy”
is also prevalent in the perinatal population, but that it might occur even more often in
pregnancy. This would not be entirely surprising as previous studies have shown that
women do have a higher threshold to use medicines during pregnancy [36–39]. Finally, the
low vaccine willingness among Swiss women is remarkable and might be explained by the
higher percentage of low educated women in the Swiss cohort and the lower proportion of
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Swiss breastfeeding participants who were professionally active. This should be further
explored in future studies.
The lack of safety data on COVID-19 vaccines in pregnancy and breastfeeding in-
creases gender-based health inequalities across the world [40,41]. Although current guide-
lines do not recommend routine vaccination of pregnant and breastfeeding women, vacci-
nating women with a high risk of exposure to SARS-CoV-2 or with underlying conditions
may be considered on an individualized basis [24–27]. Based on our findings, specific
attention should be given in clinical practice to low(er) educated and unemployed women
as they appeared to be less willing to get the vaccine. This is in line with previous stud-
ies showing the increased risk of COVID-19 vaccine hesitancy among low(er) educated
patients [28,29,32], which should alert HCPs and policy makers involved in vaccination
recommendations given its high public health importance. However, further research is
still needed to ascertain which subgroups in the perinatal population may have a higher
likelihood of COVID-19 vaccine hesitancy.
While half of the pregnant women indicated that the pandemic affected their ongoing
pregnancy experience, only a minority of breastfeeding women felt that COVID-19 had an
impact on how they personally dealt with breastfeeding. As reflected by the quotations
and described elsewhere [42,43], pregnant women attributed their negative experience
to the reduced medical follow-up, the absence of the partner during antenatal care visits
and increased anxiety or stress due to the current situation. Overall, breastfeeding women
generally denied that the pandemic influenced their breastfeeding practices. In fact, very
positive beliefs about the importance of breastfeeding in times of COVID-19 were observed,
in line with the findings of the recent study in Belgium [17]. However, breastfeeding women
also reported disruptions to medical and social support services, as shown earlier [18,44]. It
cannot be excluded that insufficient support from an HCP or other childcare responsibilities
at home led to premature breastfeeding cessation in individual cases. Therefore, HCPs
are advised to consider the patient-specific context or home situation when counseling
breastfeeding women in the future.
4.2. Strengths and Limitations
This multinational study was initiated within the European Network of Teratology
Information Services (ENTIS). The participation of six countries resulted in a large sample
size (>16,000 women). A uniform data collection instrument was used across all countries
at the same time (except Belgium), allowing for a comparison of the findings between
countries. The findings on vaccine willingness are among the first to be reported in a
perinatal population and convey an important aspect that should not be neglected in the
ongoing debate on COVID-19 vaccination guidance in pregnancy and breastfeeding. The
findings on perinatal experiences and practices, including women’s quotations, provide
salient evidence on the impact of the pandemic, thereby identifying opportunities for the
organization of perinatal care during and in the wake of the pandemic.
Some limitations should also be considered regarding the validity of the findings.
First, our findings on COVID-19 vaccine willingness should be interpreted in light of the
fact that no vaccine candidates were approved or under review in Europe at the time of
survey completion, and that the data were collected before the first reports on the efficacy
of COVID-19 vaccine candidates were published. Official recommendations on the vacci-
nation of pregnant and breastfeeding women were also not available at that time yet. It is
reasonable to assume that such events could influence people’s perceptions. Due to the
overall lack of published data on COVID-19 vaccine willingness in the perinatal population,
we could basically only compare our estimates with data obtained from the general public.
The different timing of survey completion across countries along with the different stage of
the pandemic and restrictions in place further impede the generalizability of the findings.
Second, an online survey using self-reported measures was applied, entailing the risk of
selection bias. Overall, participants were more frequently in a relationship, higher edu-
cated, professionally active (often in healthcare) and non-smokers compared to the general
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birthing population in each country [16]. As women with a low(er) education attainment
and without employment tend to be less likely to get vaccinated [28,29,32], the percentage
of vaccine willingness observed in our perinatal sample might be an overestimation of
the actual situation. This could, for example, mask evidence of a higher threshold for
COVID-19 vaccination among pregnant and breastfeeding women. The large proportion
of women who were breastfeeding for > 6 months might have contributed to the overall
lack of self-reported impact of the pandemic on breastfeeding experiences and practices
as well as the positive perceptions towards breastfeeding in our sample. However, as the
breastfeeding experiences were so predominantly positive, we believe they reflect the ac-
tual situation. The cross-sectional study design and the lack of longitudinal data collection
further prevented us from drawing conclusions on temporal changes in vaccine willingness
and on the impact of COVID-19 on the initiation and total duration of breastfeeding during
the pandemic. Third, neither qualitative data on potential reasons explaining vaccine
hesitancy nor data on the type of information women need about COVID-19 vaccines or
how to deliver it were collected. The specific reason for SARS-CoV-2 testing of individual
women also remained unknown, as well as information on race, ethnicity or socioeconomic
status. Lastly, only a few UK residents participated in this study, thus requiring careful
interpretation of the UK findings.
4.3. Future Perspectives
The specific timing when this study was performed, covering the first wave of the
pandemic, should be considered when interpreting the findings on vaccine willingness.
Future studies are needed to investigate pregnant and breastfeeding women’s vaccine
willingness at a later stage of the pandemic, at a time when COVID-19 vaccines are being
given to the general public on a large scale. Moreover, it would be interesting to assess
whether pregnant women indeed have a higher threshold for COVID-19 vaccination
compared to their breastfeeding counterparts. Equally important, and to optimally tackle
COVID-19 vaccine hesitancy, potential drivers and barriers of vaccine confidence among
pregnant and breastfeeding women could be explored, as well as the link between vaccine
confidence and uptake in these groups. Knowledge about determinants of vaccine distrust
and acceptance will allow the development of relevant interventions (e.g., information
campaigns) aimed at increasing vaccine coverage, especially in high-risk patients [45].
The exclusion of the perinatal population from COVID-19 vaccine trials, and conse-
quently, the lack of safety data of vaccine candidates is challenging for clinical practice,
especially given that so many front-line healthcare workers are women of reproductive
age [40,41]. Recently, COVID-19 surveillance systems have been set up in multiple coun-
tries and are imperative to closely monitor the utilization and safety of COVID-19 vaccines
and different vaccine platforms in pregnant and breastfeeding women [46]. More safety
data will allow HCPs to provide reliable, evidence-based and uniform information to
patients in case of, for example, unplanned pregnancies after vaccination.
Finally, the pandemic reduced women’s contact with HCPs and support services. It
is likely that the pandemic accelerated the wide usage of telemedicine [47]. However, to
guarantee successful implementation, it would be pivotal to investigate how patients and
HCPs perceive technology-assisted medicine and the usage of mobile health applications
for remote reproductive health care.
5. Conclusions
Despite differences across countries, COVID-19 vaccine hesitancy was identified
among 40–50% of the pregnant and breastfeeding women at the end of the first wave of the
pandemic and was higher among pregnant women. Education level and employment status
were associated with vaccine hesitancy. The first wave had an adverse impact on pregnancy
experiences and disrupted access to health services and breastfeeding support for many
women. However, the pandemic stimulated many women to continue breastfeeding,
although premature breastfeeding cessation due to insufficient support cannot be excluded
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in some cases. In the future, access to health care and support should be maintained at
all times. Evidence-based and tailored information on the safety and efficacy of COVID-
19 vaccines should also be provided to pregnant and breastfeeding women to avoid
unfounded concerns about the vaccines and to support shared decision making in this
population.
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